Glufosfamide

• Description :

  Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419) . Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma[1][2][3].

• CAS Number :

  [132682-98-5]

• Product Name Alternative :

  D 19575; Glucosylifosfamide mustard

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Bcl-2 Family; Caspase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/GLUFOSFAMIDE.html

• Purity :

  98.0

• Solubility :

  H2O : 125 mg/mL (ultrasonic)

• Smiles :

  O[C@@H]1[C@@H](O)[C@H](OP(NCCCl)(NCCCl)=O)O[C@H](CO)[C@H]1O

• Molecular Formula :

  C10H21Cl2N2O7P

• Molecular Weight :

  383.16

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ahmed DE, et al. An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart. J Egypt Natl Canc Inst. 2021 Aug 23;33 (1) :22. |[2]Ammons WS, et al. A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9 (8) :625-33. |[3]Attia RT, et al. The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells. PeerJ. 2016 Jun 29;4:e2168.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3